NASDAQ:ASRTAssertio Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Assertio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.80 -0.01 (-1.57 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$0.79Now: $0.80▼$0.8450-Day Range$0.78MA: $0.88▼$1.0852-Week Range$0.55Now: $0.80▼$1.71Volume687,600 shsAverage Volume1.53 million shsMarket Capitalization$64.69 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAssertio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Assertio Therapeutics has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageAssertio Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAssertio Therapeutics has received 64 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAssertio Therapeutics has received 65 “underperform” votes. (Add your “underperform” vote.)Community SentimentAssertio Therapeutics has received 50.39% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Assertio Therapeutics and other stocks. Vote “Outperform” if you believe ASRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASRT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAssertio Therapeutics does not currently pay a dividend.Dividend GrowthAssertio Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.69% of the stock of Assertio Therapeutics is held by insiders.Percentage Held by Institutions65.98% of the stock of Assertio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Assertio Therapeutics are expected to grow in the coming year, from ($1.56) to ($0.03) per share. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASRT Previous Symbol CUSIPN/A CIKN/A Webwww.assertiotx.com Phone224-419-7106Debt Debt-to-Equity Ratio1.08 Current Ratio1.01 Quick Ratio0.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$229.50 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.76Profitability EPS (Most Recent Fiscal Year)($3.07) Net Income$-217,200,000.00 Net Margins-117.10% Return on Equity-153.61% Return on Assets-39.49%Miscellaneous EmployeesN/A Outstanding Shares81,375,000Market Cap$64.69 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $0.80 -0.01 (-1.57 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ASRT News and Ratings via Email Sign-up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Assertio Therapeutics (NASDAQ:ASRT) Frequently Asked Questions How has Assertio Therapeutics' stock been impacted by COVID-19? Assertio Therapeutics' stock was trading at $0.9301 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ASRT stock has decreased by 14.5% and is now trading at $0.7950. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Assertio Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Assertio Therapeutics. When is Assertio Therapeutics' next earnings date? Assertio Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Assertio Therapeutics. How were Assertio Therapeutics' earnings last quarter? Assertio Therapeutics, Inc. (NASDAQ:ASRT) posted its earnings results on Monday, May, 11th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.18. The company earned $20.92 million during the quarter, compared to analysts' expectations of $11.30 million. Assertio Therapeutics had a negative return on equity of 153.61% and a negative net margin of 117.10%. View Assertio Therapeutics' earnings history. What price target have analysts set for ASRT? 1 brokers have issued 12 month price objectives for Assertio Therapeutics' shares. Their forecasts range from $3.50 to $3.50. On average, they anticipate Assertio Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 340.3% from the stock's current price. View analysts' price targets for Assertio Therapeutics. Has Assertio Therapeutics been receiving favorable news coverage? Media headlines about ASRT stock have trended negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Assertio Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Assertio Therapeutics. Are investors shorting Assertio Therapeutics? Assertio Therapeutics saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 3,450,000 shares, a decline of 68.9% from the January 31st total of 11,100,000 shares. Based on an average daily volume of 2,830,000 shares, the short-interest ratio is presently 1.2 days. View Assertio Therapeutics' Short Interest. Who are some of Assertio Therapeutics' key competitors? Some companies that are related to Assertio Therapeutics include Northwest Biotherapeutics (NWBO), Abeona Therapeutics (ABEO), Ritter Pharmaceuticals (RTTR), Urovant Sciences (UROV), Verastem (VSTM), Lannett (LCI), Fortress Biotech (FBIO), Trevena (TRVN), IDEAYA Biosciences (IDYA), OrganiGram (OGI), Evelo Biosciences (EVLO), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), Aquestive Therapeutics (AQST) and Marinus Pharmaceuticals (MRNS). View all competitors. What other stocks do shareholders of Assertio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio Therapeutics investors own include Actinium Pharmaceuticals (ATNM), InterDigital Wireless (IDCC), Sorrento Therapeutics (SRNE), Biocept (BIOC), Bank of Hawaii (BOH), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), T2 Biosystems (TTOO), VBI Vaccines (VBIV) and Enphase Energy (ENPH). Who are Assertio Therapeutics' key executives? Assertio Therapeutics' management team includes the following people: Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54) What is Assertio Therapeutics' stock symbol? Assertio Therapeutics trades on the NASDAQ under the ticker symbol "ASRT." Who are Assertio Therapeutics' major shareholders? Assertio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.98%), TSP Capital Management Group LLC (0.62%), Lenox Wealth Advisors LLC (0.61%), WINTON GROUP Ltd (0.40%), UBS Group AG (0.23%) and Deltec Asset Management LLC (0.14%). Company insiders that own Assertio Therapeutics stock include Arthur J Higgins, Daniel A Peisert, Karen A Dawes, Peter D Staple, Stan Bukofzer and William Mckee. View institutional ownership trends for Assertio Therapeutics. Which institutional investors are selling Assertio Therapeutics stock? ASRT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Russell Investments Group Ltd., UBS Group AG, Deltec Asset Management LLC, and First Quadrant L P CA. View insider buying and selling activity for Assertio Therapeutics. Which institutional investors are buying Assertio Therapeutics stock? ASRT stock was acquired by a variety of institutional investors in the last quarter, including Lenox Wealth Advisors LLC, TSP Capital Management Group LLC, WINTON GROUP Ltd, Ahrens Investment Partners LLC, and Nisa Investment Advisors LLC. Company insiders that have bought Assertio Therapeutics stock in the last two years include Arthur J Higgins, Daniel A Peisert, Peter D Staple, and Stan Bukofzer. View insider buying and selling activity for Assertio Therapeutics. How do I buy shares of Assertio Therapeutics? Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Assertio Therapeutics' stock price today? One share of ASRT stock can currently be purchased for approximately $0.80. How big of a company is Assertio Therapeutics? Assertio Therapeutics has a market capitalization of $64.69 million and generates $229.50 million in revenue each year. The company earns $-217,200,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis. What is Assertio Therapeutics' official website? The official website for Assertio Therapeutics is www.assertiotx.com. How can I contact Assertio Therapeutics? Assertio Therapeutics' mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The company can be reached via phone at 224-419-7106 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
